A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2013
At a glance
- Drugs Methylprednisolone; Panobinostat
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 11 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Aug 2010 New trial record